Form D · Biotechnology
Prosensa Holding N.V.
Leiden, P7 · CIK 0001574111
Offering snapshot reported Dec 8, 2014 · SEC filing
- Reported sold
- $50.5M Offering amount: $50.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 26, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 8, 2014 | Initial | $50,488,095 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-229654
The US dollar amount is converted from the Euro amount (EUR 40,355,125.10 ) based on the exchange rate on November 26, 2014.
Source: Form D, filed Dec 8, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Giles Campion | Executive |
| Luc Dochez | Executive |
| Daan Ellens | Director |
| Georges Gemayel | Director |
| Peter Goodfellow | Director |
| Annalisa Jenkins | Director |
| Martijn Kleijwegt | Director |
| Berndt Modig | Executive |
| David Mott | Director |
| Hans Schikan | Executive |
| Michael Wyzga | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
J.H. Oortweg 21
Leiden, P7, 2333 CH
Leiden, P7, 2333 CH